High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial
暂无分享,去创建一个
David P. Smith | M. Fenech | V. Gebski | D. Gillatt | M. Frydenberg | J. Yaxley | R. Gardiner | B. Armstrong | M. Kimlin | H. Gurney | J. Symons | Manish I. Patel | D. Espinoza | K. Rasiah | V. Nair-Shalliker | H. Woo | N. Awad
[1] D. Nieboer,et al. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. , 2020, European urology oncology.
[2] C. Larsson,et al. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players , 2019, Oncogene.
[3] J. Yaxley,et al. Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital , 2019, World Journal of Urology.
[4] A. D'Amico,et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] D M Parkin,et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options , 2018, The Journal of urology.
[9] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.
[10] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.
[11] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[12] E. Giovannucci,et al. Plasma vitamin D biomarkers and leukocyte telomere length in men , 2017, European Journal of Nutrition.
[13] C. Camargo,et al. Serum 25-Hydroxyvitamin D Has a Modest Positive Association with Leukocyte Telomere Length in Middle-Aged US Adults. , 2017, The Journal of nutrition.
[14] M. Mazidi,et al. The association of telomere length and serum 25-hydroxyvitamin D levels in US adults: the National Health and Nutrition Examination Survey , 2016, Archives of medical science : AMS.
[15] P. Nelson,et al. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[16] H. Lepor,et al. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. , 2016, The Journal of urology.
[17] L. Klotz,et al. Active Surveillance for Intermediate Risk Prostate Cancer , 2016, Prostate Cancer and Prostatic Diseases.
[18] J. Fütterer,et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.
[19] E. Giovannucci,et al. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer , 2015, British Journal of Cancer.
[20] M. Fenech,et al. The association between personal sun exposure, serum vitamin D and global methylation in human lymphocytes in a population of healthy adults in South Australia. , 2014, Mutation research.
[21] B. Rosner,et al. Plasma vitamin D biomarkers and leukocyte telomere length. , 2013, American journal of epidemiology.
[22] M. Roobol,et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.
[23] T. H. van der Kwast,et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. , 2013, The Journal of clinical endocrinology and metabolism.
[24] J. Carlin,et al. Recruitment and results of a pilot trial of vitamin D supplementation in the general population of Australia. , 2012, The Journal of clinical endocrinology and metabolism.
[25] P. Kruk,et al. 1,25-Dihydroxyvitamin D3 Suppresses Telomerase Expression and Human Cancer Growth through MicroRNA-498* , 2012, The Journal of Biological Chemistry.
[26] M. Fenech,et al. Sunlight and vitamin D affect DNA damage, cell division and cell death in human lymphocytes: a cross-sectional study in South Australia. , 2012, Mutagenesis.
[27] M. Fenech,et al. Does vitamin D protect against DNA damage? , 2012, Mutation research.
[28] E. Garrett-Mayer,et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. , 2012, The Journal of clinical endocrinology and metabolism.
[29] M. Fenech,et al. Dietary reference values of individual micronutrients and nutriomes for genome damage prevention: current status and a road map to the future. , 2010, The American journal of clinical nutrition.
[30] A. D'Amico,et al. Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.
[31] M. Fenech. Cytokinesis-block micronucleus cytome assay , 2007, Nature Protocols.
[32] H. Norppa,et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. , 2000, Cancer research.
[33] C. Catalano,et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.
[34] J. Campisi,et al. Cell senescence: role in aging and age-related diseases. , 2014, Interdisciplinary topics in gerontology.